Document is current
Any future updates will be listed below
-
Authors
Liu, Xiang
Ng, Wern Hann
Zusinaite, Eva
Freitas, Joseph https://orcid.org/0000-0003-3104-6282
Taylor, Adam
Yerragunta, Venugopal
Aavula, Shukra Madhaha
Gorriparthi, Sambaiah
Ponsekaran, Santhakumar
Bonda, Rama Lakshmi
Mani, Priyanka
Nimmagadda, Sridevi V.
Wang, Sainan https://orcid.org/0000-0002-7046-4965
Lello, Laura Sandra
Zaid, Ali https://orcid.org/0000-0002-2528-2783
Dua, Ujjwal
Taft-Benz, Sharon A.
Anderson, Elizabeth https://orcid.org/0000-0001-7877-1639
Baxter, Victoria K.
Sarkar, Sanjay
Ling, Zheng L.
Ashhurst, Thomas M. https://orcid.org/0000-0001-7269-7773
Cheng, Samuel M. S. https://orcid.org/0000-0001-7293-2331
Pattnaik, Priyabrata https://orcid.org/0000-0002-2314-0052
Kanakasapapathy, Anand Kumar
Baric, Ralph S. https://orcid.org/0000-0001-6827-8701
Burt, Felicity J. https://orcid.org/0000-0002-7238-7799
Peiris, Malik https://orcid.org/0000-0001-8217-5995
Heise, Mark T. https://orcid.org/0000-0001-5829-8477
King, Nicholas J. C. https://orcid.org/0000-0002-3877-9772
Merits, Andres
Lingala, Rajendra
Mahalingam, Suresh https://orcid.org/0000-0003-3141-8410
-
Funding
Funding for this research was provided by:
Department of Health | National Health and Medical Research Council (1154347)
Indian Immunologicals Ltd
- License Information
-
More Information
Article History
Received: 6 May 2024
Accepted: 7 August 2024
First Online: 26 August 2024
Competing interests
: Suresh Mahalingam, Xiang Liu, and Andres Merits are inventors of the live-attenuated SARS-CoV-2 vaccine CDO-7N-1, which has been licensed to Indian Immunologicals Ltd for further development. The study was funded by Indian Immunologicals Ltd. Venugopal Yerragunta, Shukra Madhaha Aavula, Sambaiah Gorriparthi, Santhakumar Ponsekaran, Rama Lakshmi Bonda, Priyanka Mani, Sridevi V. Nimmagadda, Priyabrata Pattnaik, Anand Kumar Kanakasapapathy, and Rajendra Lingala are employees of Indian Immunologicals Ltd. The remaining authors declare no competing interests.
